HF-POLARIS
Brief description of study
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo.
Detailed description of study
Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before. The study will include around 5600 people. Participants will be in the study for about 3 years depending on when they join.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 18 years - 99 years
-
Gender: All
Inclusion Criteria
- Body Mass Index (BMI) greater than or equal to (>=) 30 kilograms per square metre (kg/m^2) at screening.
- Diagnosis of HF with New York Heart Association (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator.
- For participants with Type 2 Diabetes (T2D) at screening: diagnosed with T2D less than or equal to 30 days before screening
Exclusion Criteria
- MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization
- Severe pulmonary disease
- Any other condition judged by the investigator to be the cause of HF symptoms (e.g., anaemia, hypothyroidism)
- Glycaemia-related:
- History of type 1 diabetes
- Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor
- Glycated haemoglobin (HbA1c) greater than (>) 10 percent (%) (86 [millimoles per mole] mmol/mol)
Please choose between Voice or SMS based delivery of verification code
or